BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 16869345)

  • 21. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
    Rostom A; Moayyedi P; Hunt R;
    Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk Factors for Upper GI Damage in Low-Dose Aspirin Users and the Interaction Between H. pylori Infection and Low-Dose Aspirin Use.
    Iijima K; Shimosegawa T
    Curr Pharm Des; 2015; 21(35):5056-65. PubMed ID: 26369687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastrointestinal injury from NSAID therapy. How to reduce the risk of complications.
    Lanas A
    Postgrad Med; 2005 Jun; 117(6):23-8, 31. PubMed ID: 16001765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction of Helicobacter pylori infection and low-dose aspirin in the upper gastrointestinal tract: implications for clinical practice.
    Leung Ki EL; Chan FK
    Best Pract Res Clin Gastroenterol; 2012 Apr; 26(2):163-72. PubMed ID: 22542154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Risk of gastrointestinal bleeding with aspirin and platelet antiaggregants].
    Nardulli G; Lanas A
    Gastroenterol Hepatol; 2009 Jan; 32(1):36-43. PubMed ID: 19174098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management.
    Chan FK
    Drug Saf; 2005; 28(4):287-300. PubMed ID: 15783239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications.
    Peura DA
    Am J Med; 2004 Sep; 117 Suppl 5A():63S-71S. PubMed ID: 15478855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey.
    Chey WD; Eswaren S; Howden CW; Inadomi JM; Fendrick AM; Scheiman JM
    Aliment Pharmacol Ther; 2006 Mar; 23(5):655-68. PubMed ID: 16480405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Nonsteroidal Anti-inflammatory Drug and Aspirin-induced Peptic Ulcer Disease].
    Shim YK; Kim N
    Korean J Gastroenterol; 2016 Jun; 67(6):300-12. PubMed ID: 27312830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs.
    McCarthy DM
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):755-73. PubMed ID: 11566039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NSAIDs-induced gastrointestinal damage. Review.
    Arroyo M; Lanas A
    Minerva Gastroenterol Dietol; 2006 Sep; 52(3):249-59. PubMed ID: 16971869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice.
    Lanas A
    Expert Opin Drug Saf; 2011 Jan; 10(1):45-54. PubMed ID: 20645883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond.
    Becker JC; Domschke W; Pohle T
    Br J Clin Pharmacol; 2004 Dec; 58(6):587-600. PubMed ID: 15563357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Role of Helicobacter pylori in drug-induced gastrointestinal bleeding].
    Chaussade S; Abitbol V
    Presse Med; 2003 Nov; 32(37 Pt 2):S60-3. PubMed ID: 14763358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs.
    Pilotto A; Franceschi M; Leandro G; Paris F; Cascavilla L; Longo MG; Niro V; Andriulli A; Scarcelli C; Di Mario F
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1091-7. PubMed ID: 15569111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs.
    Peng S; Duggan A
    Expert Opin Drug Saf; 2005 Mar; 4(2):157-69. PubMed ID: 15794710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peptic ulcer disease today.
    Yuan Y; Padol IT; Hunt RH
    Nat Clin Pract Gastroenterol Hepatol; 2006 Feb; 3(2):80-9. PubMed ID: 16456574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
    Targownik LE; Metge CJ; Leung S; Chateau DG
    Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks.
    Chan FK
    Nat Clin Pract Gastroenterol Hepatol; 2006 Oct; 3(10):563-73. PubMed ID: 17008926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding NSAID-PPI-COX-2 interrelationships.
    Singh G
    Drugs Today (Barc); 2004 Mar; 40 Suppl A():21-4. PubMed ID: 15190384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.